Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.
University Hospital for Cranio-Maxillofacial and Oral Surgery and CMF Institute Vienna, Vienna, Austria.
Clin Oral Investig. 2022 Nov;26(11):6569-6582. doi: 10.1007/s00784-022-04609-4. Epub 2022 Aug 24.
To investigate the effects of antiresorptive treatment on the survival of plateau-root form dental implants.
Patients undergoing antiresorptive therapy via oral or intravenous administration as well as patients not undergoing antiresorptive therapy and healthy control patients were included in this retrospective cohort study. In total, 1472 implants placed in 631 postmenopausal patients (M: 66.42 ± 9.10 years old), who were followed for a period of up to 20 years (8.78 ± 5.68 years). Kaplan-Meier survival analysis was performed, and univariate and multivariate Cox regression, clustered by each patient, was used to evaluate and study factors affecting the survival of their implants.
Implants placed in patients undergoing oral antiresorptive treatment presented significantly higher survival rates, than implants placed in the osteoporosis/osteopenia control cohort (p value < 0.001), and similar survival rates, when compared to healthy controls (p value = 0.03). Additionally, clustered univariate and multivariate Cox regression analysis also revealed higher implant survival when oral antiresorptive drugs (p value = 0.01 and 0.007, respectively) were used, and lower implant survival in the presence of untreated osteoporosis/osteopenia (p value = 0.002 and 0.005, respectively). Overall, the 20-year implant survival in osteoporotic patients undergoing antiresorptive therapy was 94%. For the failed implants, newly replaced implants in patients under antiresorptive treatment presented a 10-year survival of 89%.
Long-term plateau-root form implant survival in osteoporotic patients taking oral antiresorptives was similar to a healthy population and significantly higher than the untreated controls.
These results suggest that plateau-root form implants provide a robust solution for treating tooth loss in patients, who are undergoing antiresorptive therapy.
研究抗吸收治疗对高原根型牙种植体存活率的影响。
本回顾性队列研究纳入了接受口服或静脉内抗吸收治疗的患者、未接受抗吸收治疗的患者以及健康对照组患者。共纳入 631 名绝经后患者(M:66.42±9.10 岁)的 1472 枚种植体,随访时间长达 20 年(8.78±5.68 年)。采用 Kaplan-Meier 生存分析,并对每个患者进行单变量和多变量 Cox 回归分析,以评估和研究影响种植体存活率的因素。
与骨质疏松/骨量减少对照组相比(p 值<0.001),接受口服抗吸收治疗的患者植入的种植体存活率显著更高,与健康对照组相比(p 值=0.03),其存活率相似。此外,聚类的单变量和多变量 Cox 回归分析还显示,使用口服抗吸收药物时种植体存活率更高(p 值分别为 0.01 和 0.007),而未治疗的骨质疏松/骨量减少时种植体存活率较低(p 值分别为 0.002 和 0.005)。总体而言,接受抗吸收治疗的骨质疏松患者的 20 年种植体存活率为 94%。对于失败的种植体,接受抗吸收治疗的患者新更换的种植体 10 年存活率为 89%。
接受口服抗吸收治疗的骨质疏松患者的长期高原根型种植体存活率与健康人群相似,明显高于未治疗的对照组。
这些结果表明,高原根型种植体为接受抗吸收治疗的患者提供了一种可靠的治疗牙齿缺失的方法。